Propanc Biopharma Inc
OTC:PPCB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Ilsung Pharmaceutical Co Ltd
KRX:003120
|
KR |
|
G
|
Gadsden Properties Inc
OTC:GADS
|
US |
Propanc Biopharma Inc
Total Current Liabilities
Propanc Biopharma Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Propanc Biopharma Inc
OTC:PPCB
|
Total Current Liabilities
$3.8m
|
CAGR 3-Years
7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Total Current Liabilities
$128.1m
|
CAGR 3-Years
33%
|
CAGR 5-Years
7%
|
CAGR 10-Years
12%
|
|
|
CSL Ltd
ASX:CSL
|
Total Current Liabilities
$4.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
12%
|
CAGR 10-Years
14%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Total Current Liabilities
AU$1.2m
|
CAGR 3-Years
11%
|
CAGR 5-Years
59%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Total Current Liabilities
AU$231.6m
|
CAGR 3-Years
39%
|
CAGR 5-Years
63%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Total Current Liabilities
AU$11m
|
CAGR 3-Years
11%
|
CAGR 5-Years
57%
|
CAGR 10-Years
29%
|
|
Propanc Biopharma Inc
Glance View
Propanc Biopharma, Inc. is a development-stage healthcare company, which engages in the research and development of cancer treatments. The firm has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate PRP is a pharmaceutical composition consisting of two pancreatic proenzymes trypsinogen and chymotrypsinogen for treating cancer. PRP is an approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that targets and eradicates cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers. PRP is a therapy based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas and could represent the body’s primary defense against cancer.
See Also
What is Propanc Biopharma Inc's Total Current Liabilities?
Total Current Liabilities
3.8m
USD
Based on the financial report for Jun 30, 2024, Propanc Biopharma Inc's Total Current Liabilities amounts to 3.8m USD.
What is Propanc Biopharma Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 3Y
7%
Over the last year, the Total Current Liabilities growth was 20%. The average annual Total Current Liabilities growth rates for Propanc Biopharma Inc have been 7% over the past three years .
